Nucleome Therapeutics
Nucleome Therapeutics is an Oxford University spinout using proprietary Micro Capture-C 3D genomics and machine learning to decode the non-coding genome and identify novel antibody drug targets for immune-mediated inflammatory diseases, with lead candidate NTP464 advancing toward Phase 1 in 2027.
- Company typePrivate
- Founded2019
- HeadquartersOxford, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Nucleome Therapeutics does
Nucleome Therapeutics is a UK-based preclinical biotechnology company, spun out of the University of Oxford in 2019 and headquartered in Oxford, that decodes the non-coding ('dark') genome to identify causal drug targets for immune-mediated inflammatory diseases. Its proprietary Micro Capture-C (MCC) platform provides single base-pair resolution mapping of 3D chromatin interactions, physically linking non-coding disease-associated variants to the genes they dysregulate; MCC is exclusively licensed from Oxford University and protected by US Patent No. US12,674,197 (granted July 2026), with additional patents covering its Variant Functional Validation (VFV) technology granted in 2025. The company combines this wet-lab assay with deep-learning models and its proprietary 'Nucleome Genetic Score' to produce a Disease Atlas covering hundreds of dysregulated genes across multiple inflammatory cell types, and has retrospectively demonstrated a 4x improvement in clinical success rate over industry standard for drug target selection in inflammatory diseases.
The lead in-house programme is NTP464, a first-in-class monoclonal antibody agonist targeting a novel inflammation checkpoint, nominated in January 2026 for chronic inflammatory diseases including rheumatoid arthritis, lupus, and IBD, with IND-enabling studies underway and Phase 1 commencement targeted for 2027. Nucleome operates a dual business model: building its own antibody pipeline while selectively partnering with pharmaceutical companies — it has a current collaboration with a major (unnamed) pharma partner — to monetize targets, biomarkers, and patient stratification insights via licensing, milestone payments, and royalties. The company is venture-backed (Series A of £37.5M closed October 2022 led by M Ventures, with Pfizer Ventures, JJDC, British Patient Capital, and Oxford Science Enterprises) and led by an experienced team including CEO Dr. Mark Bodmer (formerly SVP at GSK and CSO at Evelo Biosciences), CSO Dr. Michelle Morrow (appointed February 2026), CTO Dr. Jonny Wray, and CBO Bhavna Hunjan.
Nucleome Therapeutics firmographics
Firmographics- Name
- Nucleome Therapeutics
- Legal name
- Nucleome Therapeutics Limited
- Website
- https://nucleome.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Nucleome Therapeutics is an Oxford University spinout using proprietary Micro Capture-C 3D genomics and machine learning to decode the non-coding genome and identify novel antibody drug targets for immune-mediated inflammatory diseases, with lead candidate NTP464 advancing toward Phase 1 in 2027.
- Ownership category
- akta.pro rank
Nucleome Therapeutics industry classification
Industry- Product category
- Biotechnology / Inflammatory Disease Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where Nucleome Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Nucleome Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Partnerships: Nucleome is selectively partnering with pharmaceutical companies to identify targets and responsive patients in various therapeutic areas. Revenue would come from upfront payments, milestone payments, and royalties from partnership deals.
- Drug Development and Commercialization: Developing proprietary pipeline of antibody therapeutics for inflammatory diseases with lead programme NTP464 in preclinical development. Revenue would come from product sales if drugs are approved and commercialized.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Nucleome Therapeutics product offering
Product offeringCore offering
Nucleome Therapeutics applies proprietary 3D genomics technology (Micro Capture-C) to decode the non-coding (regulatory) genome of the human genome and identify causal drug targets in inflammatory and autoimmune diseases. The company combines this platform with machine learning and functional genomics to build a proprietary disease atlas, discover novel therapeutic targets, and advance an internal pipeline of antibody therapeutics led by NTP464, while selectively partnering with pharmaceutical companies for target identification and co-development.
Product overview
Nucleome Therapeutics operates as an immunology company offering a proprietary 3D genomics platform combined with AI/ML capabilities to decode the regulatory (non-coding) genome for inflammatory disease drug discovery. The core product is the Micro Capture-C (MCC) Platform, which provides base-pair resolution mapping of 3D genomic interactions to identify functional disease variants and novel drug targets. The lead development candidate is NTP464, a first-in-class monoclonal antibody agonist for inflammation resolution currently in pre-clinical development. The company is building a pipeline of genetically-identified antibody therapeutics targeting inflammatory diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- NTP464 NTP464 is Nucleome's lead preclinical development candidate, a first-in-class monoclonal antibody agonist targeting a novel inflammation checkpoint for chronic inflammatory diseases including rheumatoid arthritis, lupus, and inflammatory bowel disease. It demonstrated efficacy in preclinical assays by inhibiting B cell, T cell, and macrophage activation while promoting Treg suppressive activities. Clinical trial application and Phase 1 commencement are targeted for 2027.
- Micro Capture-C (MCC) Platform The Micro Capture-C (MCC) Platform is Nucleome's proprietary 3D genomics technology that provides base-pair resolution mapping of chromatin interactions, physically linking regulatory elements in the non-coding genome to the genes they control. Exclusively licensed from Oxford University, it underpins the company's target identification work and is offered to pharmaceutical partners as the foundation of collaboration deals.
Quantifiable outcome
- 4x increase in clinical success rate for drug targets selected using Nucleome technology compared to industry standard
- +2 more outcomes
Companies that use Nucleome Therapeutics
Customer profileSegments2 records
Ideal customer profiles1 record
Nucleome Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
Nucleome Therapeutics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core, minor and major.
- Weatherall Institute of Molecular Medicine, Oxford UniversitycoreCollaborative research with Professor James Davies and researchers at the Weatherall Institute of Molecular Medicine resulted in a groundbreaking publication in Cell journal demonstrating base-pair resolution DNA folding and function using MCC technology.
- University of Cambridge - Professor Rosana Collepardo-GuevaraminorCollaborated with Professor Rosana Collepardo-Guevara at University of Cambridge for computer simulations confirming that folding patterns observed in MCC technology arise naturally from the physical properties of DNA and its packaging proteins.
- Oxford UniversitycoreNucleome holds an exclusive license from Oxford University to the Micro Capture-C (MCC) technology. The technology was developed by Professors Jim Hughes and James Davies at Oxford's Weatherall Institute of Molecular Medicine. Nucleome is actively collaborating with researchers at Oxford University, including a 2025 publication in Cell journal.
- Major Pharmaceutical Company (unnamed)majorNucleome is collaborating with a major pharmaceutical company and foresees multiple opportunities to collaborate with other companies to identify targets and responsive patients in various therapeutic areas.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Nucleome Therapeutics competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Nucleome Therapeutics social profiles
Digital presenceNucleome Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nucleome Therapeutics leadership team
Management profileNumber of profiles
Profiles14 records
Nucleome Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nucleome Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nucleome Therapeutics
What does Nucleome Therapeutics do?
Nucleome Therapeutics applies proprietary 3D genomics technology (Micro Capture-C) to decode the non-coding (regulatory) genome of the human genome and identify causal drug targets in inflammatory and autoimmune diseases. The company combines this platform with machine learning and functional genomics to build a proprietary disease atlas, discover novel therapeutic targets, and advance an internal pipeline of antibody therapeutics led by NTP464, while selectively partnering with pharmaceutical companies for target identification and co-development.
Is Nucleome Therapeutics a public or private company?
Nucleome Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Nucleome Therapeutics founded?
Nucleome Therapeutics was founded in 2019. It employs 11 to 50 people.
Where is Nucleome Therapeutics based?
Nucleome Therapeutics is headquartered in Oxford, United Kingdom, in the Europe region.
How does Nucleome Therapeutics make money?
Two revenue lines are on record. Pharmaceutical Partnerships are the primary driver. The others are drug Development and Commercialization.
Does Nucleome Therapeutics have an API?
No public API is recorded for Nucleome Therapeutics.
What industry is Nucleome Therapeutics in?
Nucleome Therapeutics's product category is Biotechnology / Inflammatory Disease Drug Discovery. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.